Bellicum Pharmaceuticals Introduces Super-Voting Shares and Changes Quorum Requirement

Bellicum Pharmaceuticals (BLCM) has released an update to notify the public and investors about corporate charter and bylaws modifications.

On January 24, 2024, the Company registered a Certificate of Designation for Series A Junior Preferred Stock, introducing a Super-Voting Share that provides its holder with voting power equivalent to the total common shares on record for shareholder meetings, contingent on proportional voting with common shares. These Super-Voting Shares are senior to common stock and other future junior stock but junior to existing preferred stock, are non-dividend bearing, and offer a nominal liquidation preference. Additionally, the Company amended its bylaws to change the quorum requirement for stockholder meetings to a majority of the voting power instead of a majority of outstanding shares.

For further insights into BLCM corporate activity, check out TipRanks’ Insiders Trading Activity page.